Influence of metformin on HIF-1 pathway in multiple myeloma.

Kinga A Kocemba-PilarczykSonia TrojanBarbara OstrowskaMałgorzata LasotaPaulina DudzikDorota KusiorMarta Kot

Published in: Pharmacological reports : PR (2020)

Taken together, our study indicates metformin as a promising candidate for developing new treatment strategies exploiting HIF-1 signaling inhibition to enhance the overall anti-MM effect of currently used therapies, that may considerably benefit MM patients.

Keyphrases

end stage renal disease
multiple myeloma
newly diagnosed
chronic kidney disease
endothelial cells
prognostic factors
patient reported outcomes